• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DMXAA:一种具有多种宿主反应的抗血管生成剂。

DMXAA: an antivascular agent with multiple host responses.

作者信息

Baguley Bruce C, Ching Lai Ming

机构信息

Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand.

出版信息

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1503-11. doi: 10.1016/s0360-3016(02)03920-2.

DOI:10.1016/s0360-3016(02)03920-2
PMID:12459378
Abstract

PURPOSE

To measure host responses to the antivascular agent DMXAA (5,6-dimethylxanthenone-4-acetic acid) and to compare them with those of other antivascular agents.

METHODS

Induction of tumor necrosis was measured in s.c. murine Colon 38 carcinomas growing in normal or tumor necrosis factor (TNF) receptor-1 knockout mice. Plasma and tumor tissue TNF concentrations were measured by ELISA. Plasma concentrations of 5-hydroxyindoleacetic acid (as a measure of serotonin release) and nitrite (as a measure of nitric oxide release) were measured by high-performance liquid chromatography.

RESULTS

Administration of DMXAA to tumor-bearing mice increased plasma and tumor tissue-associated TNF, in addition to increasing plasma nitric oxide, distinguishing its action from that of mitotic poisons that had an antivascular action. Results from TNF receptor-1 knockout mice showed that TNF played an important role in both its antitumor action and its host toxicity. Release of serotonin occurred in response to mitotic poisons, as well as to DMXAA. CONCLUCIONS: The antivascular action of DMXAA involves in situ production in tumor tissue of a cascade of vasoactive events, including a direct effect on vascular endothelial cells and indirect vascular effects involving TNF, other cytokines, serotonin, and nitric oxide. Now that Phase I clinical trials of DMXAA are completed, the optimization of this cascade in cancer patients is a major challenge. Plasma 5-hydroxyindoleacetic acid concentrations may provide a useful surrogate marker for the antivascular effects of DMXAA and other antivascular agents.

摘要

目的

测定宿主对抗血管生成剂DMXAA(5,6 - 二甲基呫吨酮 - 4 - 乙酸)的反应,并将其与其他抗血管生成剂的反应进行比较。

方法

在正常或肿瘤坏死因子(TNF)受体 - 1基因敲除小鼠体内生长的皮下鼠结肠癌38癌中,测定肿瘤坏死的诱导情况。通过酶联免疫吸附测定法(ELISA)测量血浆和肿瘤组织中的TNF浓度。通过高效液相色谱法测量血浆中5 - 羟吲哚乙酸(作为血清素释放的指标)和亚硝酸盐(作为一氧化氮释放的指标)的浓度。

结果

给荷瘤小鼠施用DMXAA除了增加血浆一氧化氮外,还增加了血浆和肿瘤组织相关的TNF,这使其作用与具有抗血管生成作用的有丝分裂毒物的作用区分开来。TNF受体 - 1基因敲除小鼠的结果表明,TNF在其抗肿瘤作用和宿主毒性中均起重要作用。血清素的释放是对有丝分裂毒物以及DMXAA的反应。结论:DMXAA的抗血管生成作用涉及肿瘤组织中一系列血管活性事件的原位产生,包括对血管内皮细胞的直接作用以及涉及TNF、其他细胞因子、血清素和一氧化氮的间接血管作用。鉴于DMXAA的I期临床试验已经完成,在癌症患者中优化这一反应级联是一项重大挑战。血浆5 - 羟吲哚乙酸浓度可能为DMXAA和其他抗血管生成剂的抗血管生成作用提供有用的替代标志物。

相似文献

1
DMXAA: an antivascular agent with multiple host responses.DMXAA:一种具有多种宿主反应的抗血管生成剂。
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1503-11. doi: 10.1016/s0360-3016(02)03920-2.
2
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.5,6-二甲基呫吨酮-4-乙酸(DMXAA)在小鼠体内的口服活性及药代动力学
Cancer Chemother Pharmacol. 2002 Jan;49(1):20-6. doi: 10.1007/s00280-001-0377-3.
3
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.5,6-二甲基呫吨酮-4-乙酸(DMXAA)在肿瘤坏死因子受体-1基因敲除小鼠中的抗肿瘤活性。
Br J Cancer. 2002 Aug 12;87(4):465-70. doi: 10.1038/sj.bjc.6600479.
4
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.5,6-二甲基呫吨酮-4-乙酸(DMXAA)在肿瘤坏死因子基因敲除小鼠中诱导瘤内肿瘤坏死因子(TNF)合成及出血性坏死
Cancer Res. 1999 Jul 15;59(14):3304-7.
5
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).抗血管生成剂5,6-二甲基呫吨酮-4-乙酸(DMXAA)在体内对宿主细胞和肿瘤细胞中核因子κB的激活作用。
Eur J Cancer. 2003 May;39(8):1176-83. doi: 10.1016/s0959-8049(03)00196-5.
6
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).血清素受体拮抗剂赛庚啶对5,6-二甲基呫吨酮-4-乙酸(DMXAA)活性和药代动力学的影响。
Cancer Chemother Pharmacol. 2001 Jun;47(6):491-7. doi: 10.1007/s002800000267.
7
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.5,6-二甲基呫吨酮-4-乙酸(DMXAA)诱导肿瘤血管关闭的机制:肿瘤血管通透性增加。
Int J Cancer. 2005 Aug 20;116(2):322-6. doi: 10.1002/ijc.21005.
8
Antivascular therapy of cancer: DMXAA.癌症的抗血管生成疗法:DMXAA。
Lancet Oncol. 2003 Mar;4(3):141-8. doi: 10.1016/s1470-2045(03)01018-0.
9
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.使用5,6-二甲基呫吨酮-4-乙酸原位刺激肿瘤合成肿瘤坏死因子-α:一种癌症治疗的新方法。
Cancer Res. 1999 Feb 1;59(3):633-8.
10
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.测定血浆5-羟吲哚乙酸作为抗血管生成药物作用的一种可能的临床替代标志物。
Clin Chim Acta. 2001 Dec;314(1-2):159-66. doi: 10.1016/s0009-8981(01)00692-1.

引用本文的文献

1
Progress Update on STING Agonists as Vaccine Adjuvants.作为疫苗佐剂的STING激动剂的进展更新
Vaccines (Basel). 2025 Mar 31;13(4):371. doi: 10.3390/vaccines13040371.
2
Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.针对肿瘤血管供应,以增强单次或临床相关分割放疗的疗效。
Int J Mol Sci. 2024 Jul 24;25(15):8078. doi: 10.3390/ijms25158078.
3
Agonists and Inhibitors of the cGAS-STING Pathway.cGAS-STING 通路的激动剂和抑制剂。
Molecules. 2024 Jun 30;29(13):3121. doi: 10.3390/molecules29133121.
4
Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA.基于鼠 STING 激动剂 DMXAA 结构的新型 STING 抑制剂的发现。
Molecules. 2023 Mar 23;28(7):2906. doi: 10.3390/molecules28072906.
5
Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy.STING与TLR 7/8激动剂联合作为癌症免疫治疗的疫苗佐剂
Cancers (Basel). 2022 Dec 11;14(24):6091. doi: 10.3390/cancers14246091.
6
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.化学和生物分子策略在癌症免疫治疗中对 STING 通路的激活。
Chem Rev. 2022 Mar 23;122(6):5977-6039. doi: 10.1021/acs.chemrev.1c00750. Epub 2022 Feb 2.
7
Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.通过多模态免疫治疗方法靶向急性髓系白血病。
Leuk Lymphoma. 2022 Apr;63(4):918-927. doi: 10.1080/10428194.2021.1992614. Epub 2021 Nov 25.
8
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.用于癌症免疫治疗的STING激动剂临床开发中的挑战与机遇
J Clin Med. 2020 Oct 16;9(10):3323. doi: 10.3390/jcm9103323.
9
STING pathway agonism as a cancer therapeutic.STING 通路激动剂作为一种癌症治疗方法。
Immunol Rev. 2019 Jul;290(1):24-38. doi: 10.1111/imr.12765.
10
Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives.羧基呫吨酮:生物活性物质及合成类似物和衍生物的分子支架
Molecules. 2019 Jan 5;24(1):180. doi: 10.3390/molecules24010180.